ATE368054T1 - Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität - Google Patents

Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität

Info

Publication number
ATE368054T1
ATE368054T1 AT98963311T AT98963311T ATE368054T1 AT E368054 T1 ATE368054 T1 AT E368054T1 AT 98963311 T AT98963311 T AT 98963311T AT 98963311 T AT98963311 T AT 98963311T AT E368054 T1 ATE368054 T1 AT E368054T1
Authority
AT
Austria
Prior art keywords
modulating agents
occludin
cell adhesion
methods
compounds
Prior art date
Application number
AT98963311T
Other languages
English (en)
Inventor
Orest W Blaschuk
Barbara Gour
James Matthew Symonds
Original Assignee
Adherex Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adherex Technologies Inc filed Critical Adherex Technologies Inc
Application granted granted Critical
Publication of ATE368054T1 publication Critical patent/ATE368054T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98963311T 1997-12-31 1998-12-30 Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität ATE368054T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/001,511 US6248864B1 (en) 1997-12-31 1997-12-31 Compounds and methods and modulating tissue permeability

Publications (1)

Publication Number Publication Date
ATE368054T1 true ATE368054T1 (de) 2007-08-15

Family

ID=21696412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98963311T ATE368054T1 (de) 1997-12-31 1998-12-30 Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität

Country Status (9)

Country Link
US (3) US6248864B1 (de)
EP (1) EP1042365B1 (de)
JP (1) JP2002509073A (de)
AT (1) ATE368054T1 (de)
AU (1) AU764790B2 (de)
CA (1) CA2351624A1 (de)
DE (1) DE69838147T2 (de)
ES (1) ES2292211T3 (de)
WO (1) WO1999035166A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797807B1 (en) * 1997-12-31 2004-09-28 Adherex Technologies, Inc. Compounds and methods for cancer therapy
DE69942334D1 (de) * 1998-03-02 2010-06-17 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
US6391855B1 (en) * 1999-06-02 2002-05-21 Adherex Technologies, Inc. Compounds and methods for modulating junctional adhesion molecule-mediated functions
CA2384115C (en) * 1999-09-03 2016-08-02 Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US6787136B1 (en) 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
US20030153015A1 (en) * 2000-01-20 2003-08-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2001053480A1 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US20030195707A1 (en) * 2000-05-25 2003-10-16 Schork Nicholas J Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
CA2415690A1 (en) * 2000-07-14 2002-01-24 Chiron Corporation Tetraspan protein and uses thereof
AU2002226075A1 (en) * 2000-10-23 2002-05-06 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
US20020192206A1 (en) * 2001-05-05 2002-12-19 Kozarov Emil V. Methods and compositions for angioproliferative disorder treatment
WO2003014151A2 (en) * 2001-08-10 2003-02-20 Genset S.A. Human secreted proteins, their encoding polynucleotides, and uses thereof
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003247435A1 (en) * 2002-05-30 2003-12-19 European Molecular Biology Laboratory Combinatorial chemical library ii
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
EP1384469A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
EP1384468A1 (de) * 2002-07-25 2004-01-28 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Tight Junctions
CA2504768A1 (en) * 2002-11-14 2004-05-27 Adherex Technologies, Inc. Compounds and methods for modulating functions of classical cadherins
US7476509B2 (en) * 2002-11-14 2009-01-13 Adherex Technologies Inc. Compounds and methods for modulating functions of nonclassical cadherins
US20040253211A1 (en) * 2003-04-30 2004-12-16 Nastech Pharmaceutical Company Inc. Method for diagnosing and treating cancer
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
WO2006071878A1 (en) * 2004-12-28 2006-07-06 Emory Unversity Methods and compositions for treating epithelial cancers
EP1877444A2 (de) * 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin-antikörper
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
EP2064222B1 (de) 2007-04-02 2014-05-07 Theracos, Inc. Benzylische glycosidderivate und verfahren zu ihrer verwendung
AU2008288770B2 (en) 2007-08-23 2014-06-12 Theracosbio, Llc Benzylbenzene derivatives and methods of use
WO2009102367A2 (en) * 2007-11-19 2009-08-20 The Regents Of The University Of Colorado Tight junction protein modulators and uses thereof
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
MX2011001855A (es) 2008-08-22 2011-03-24 Theracos Inc Procesos para la preparacion de inhibidores de sglt2.
WO2010040001A1 (en) * 2008-10-03 2010-04-08 The Rockefeller University New hcv entry factor, occludin
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
WO2010150100A1 (en) 2009-06-24 2010-12-29 Entarco Sa The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
US8877188B2 (en) 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis
EP2576549A4 (de) 2010-05-24 2013-12-18 Univ Rochester Bizyklische heteroarylkinase-hemmer und verfahren zu ihrer verwendung
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
EP2654757A1 (de) 2010-12-22 2013-10-30 Entarco SA Verwendung von spinosynen und spinosynzusammensetzungen als lokalanästhetika und antiarrhythmika
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
EP3103808B1 (de) * 2014-02-07 2018-08-22 Miyarisan Pharmaceutical Co., Ltd. Peptid mit aktivität zur hemmung der produktion von toxins durch bakterium der gattung clostridium
JP6566444B2 (ja) 2014-03-19 2019-08-28 カーザ グローバル エルエルシーＣｕｒｚａ Ｇｌｏｂａｌ， Ｌｌｃ ２−（アシルアミノ）イミダゾールを含む組成物および方法
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
CN108084257B (zh) * 2016-11-23 2020-06-12 深圳市安群生物工程有限公司 人闭锁蛋白抗原表位肽、抗原、抗体、试剂盒及应用
JP2020512981A (ja) 2017-03-31 2020-04-30 カーザ グローバル，リミティド ライアビリティ カンパニー 置換２−アミノイミダゾールを含む組成物と方法
EP3841123A2 (de) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit-antikörper
TW202233248A (zh) 2020-11-08 2022-09-01 美商西健公司 組合療法
JP2024514816A (ja) 2021-04-09 2024-04-03 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体を用いるがんの治療方法
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024225703A1 (ko) * 2023-04-26 2024-10-31 서울대학교산학협력단 C-n 결합으로 환형화된 새로운 환형 펩타이드계열 화합물, 이의 생산 방법 및 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489460B1 (en) 1996-03-07 2002-12-03 Eisai Company, Ltd. Cloned DNA encoding mammalian occludins
US6252045B1 (en) 1996-03-15 2001-06-26 Yale University Human occludin, its uses and enhancement of drug absorption using occludin inhibitors
US6214795B1 (en) 1996-11-12 2001-04-10 Praecis Pharmaceuticals, Inc. Peptide compounds useful for modulating FGF receptor activity

Also Published As

Publication number Publication date
DE69838147T2 (de) 2008-05-29
ES2292211T3 (es) 2008-03-01
US6310177B1 (en) 2001-10-30
AU764790B2 (en) 2003-08-28
DE69838147D1 (de) 2007-09-06
EP1042365B1 (de) 2007-07-25
CA2351624A1 (en) 1999-07-15
EP1042365A1 (de) 2000-10-11
US6248864B1 (en) 2001-06-19
WO1999035166A1 (en) 1999-07-15
US6110747A (en) 2000-08-29
AU1866599A (en) 1999-07-26
JP2002509073A (ja) 2002-03-26

Similar Documents

Publication Publication Date Title
DE69838147D1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
ATE369878T1 (de) Träger-pharmaka-konjugate
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
ATE218579T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin- analogen
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
DK1093383T3 (da) Lægemiddelafgivelsessystem omfattende et homeobox-peptid og et cytotoksisk eller antineoplastisk lægemiddel
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60006100D1 (de) Lang wirkende insulinotrope peptide
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60032486D1 (de) Prion protein peptide und deren verwendung
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
DK1123414T3 (da) Antisense-modulering af integrin alpha 4.ekspression
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
MXPA04000317A (es) Un copolimero de bloque amfifilico cargado positivamente como un vehiculo de medicamento y complejo del mismo con un medicamento cargado negativamente.
EP1401467A4 (de) Alpha-fetoprotein-peptide und ihre verwendung
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties